Epigenetic fingerprint in endometrial carcinogenesis: The hypothesis of a uterine field cancerization

Cancer Biology and Therapy

Volumn 12, Issue 5, 2011, Pages 447-457

  Di Domenico, Marina ^a   Santoro, Angela ^e   Ricciardi, Carmela ^a   Iaccarino, Mirella ^b   Iaccarino, Stefania ^b   Freda, Mariagrazia ^a   Feola, Antonia ^a   Sanguedolce, Francesca ^c   Losito, Simona ^c   Pasquali, Daniela ^a   Di Spiezio Sardo, Attilio ^d   Bifulco, Giuseppe ^d   Nappi, Carmine ^d   Bufo, Pantaleo ^e   Guida, Maurizio ^d   De Rosa, Gaetano ^d   Abbruzzese, Alberto ^a   Caraglia, Michele ^a   Pannone, Giuseppe ^e  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Ospedale Internazionale   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF FOGGIA   (Italy)

Author keywords

E cadherin; Endometrial lesions; hMLH1; Methylation specific PCR; p16; SFRP1; SFRP2; SFRP4; SFRP5; Wnt pathway

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR; PROTEIN MLH1; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; SECRETED FRIZZLED RELATED PROTEIN 5;

ADULT; AGED; ARTICLE; CANCER RISK; CARCINOGENESIS; CLINICAL ARTICLE; DEMETHYLATION; DNA FINGERPRINTING; DNA METHYLATION; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; EPIGENETIC FINGERPRINT; EPIGENETICS; FEMALE; GENETIC ENGINEERING AND GENE TECHNOLOGY; HUMAN; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA MISMATCH REPAIR; ENDOMETRIAL NEOPLASMS; EPIGENESIS, GENETIC; FEMALE; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RECEPTORS, STEROID; TUMOR SUPPRESSOR PROTEIN P53; WNT SIGNALING PATHWAY;

EID: 80052364717     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.5.15963     Document Type: Article

References (68)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1997; 47:5-27; PMID: 8996076; DOI: 10.3322/canjclin.47.1.5.
2. Jemal A, Siegel R, Ward E. Cancer statistics 2006. CA Cancer J Clin 2007; 57:43-66; PMID: 17237035; DOI: 10.3322/canjclin.57.1.43.
3. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000; 7:227-42; PMID: 11174845; DOI: 10.1677/erc.0.0070227.
4. Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 2004; 11:117-42; PMID: 15096727; DOI: 10.1097/00125480-200405000- 00001.
5. Sherman AI, Brown S. The precursors of endometrial carcinoma. Am J Obstet Gynecol 1979; 135:947-56; PMID: 507134.
6. Kurman RJ, Kaminski P, Norris H. The behavior of endometrial hyperplasia: a long term study of "untreated" hyperplasia in 170 patients. Cancer 1985; 56:403-12; PMID: 4005805; DOI: 10.1002/1097-0142(19850715)56:2〈403:: AIDCNCR2820560233〉 3.0.CO;2-X.
7. Matias-Guiu X, Catasus L, Bussaglia E. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001; 32:569-77; PMID: 11431710; DOI: 10.1053/hupa.2001.25929.
8. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. Detection of clonality and genetic alterations in endometrial pipelle biopsy and its surgical specimen counterpart. Lab Invest 1997; 76:109-16; PMID: 9010454.
9. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006; 24:4783-91; PMID: 17028294; DOI: 10.1200/ JCO.2006.06.7173.
10. Di Domenico M, Castoria G, Bilancio A, Migliaccio A, Auricchio F. Estradiol activation of human colon carcinoma-derived Caco-2 cell growth. Cancer Res 1996; 56:4516-21; PMID: 8813150.
11. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93:9821-6; PMID: 8790415; DOI: 10.1073/pnas.93.18.9821.
12. Esteller M. Dormant hypermethylated tumour suppressor genes: questions and answers. J Pathol 2005; 205:172-80; PMID: 15643671; DOI: 10.1002/ path.1707.
13. Singal R, Ginder GD. DNA methylation. Blood 1999; 93:4059-70; PMID: 10361102.
14. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-28; PMID: 12042769.
15. Vicent GP, Zaurin R, Nacht AS, Li A, Font-Mateu J, Le Dily F, et al. Two chromatin remodeling activities cooperate during activation of hormone responsive promoters. PLoS Genet 2009; 5:1000567; PMID: 19609353; DOI: 10.1371/journal.pgen.1000567.
16. Chan QK, Khoo US, Chan KY, Ngan HY, Li SS, Chiu PM, et al. Promoter methylation and differential expression of pi-class glutathione S-transferase in endometrial carcinoma. J Mol Diagn 2005; 7:8-16; PMID: 15681469; DOI: 10.1016/S1525-1578(10)60003-7.
17. Li R, Saito T, Tanaka R, Satohisa S, Adachi K, Horie M, et al. Hypermethylation in promoter region of retinoic acid receptor-beta gene and immunohistochemical findings on retinoic acid receptors in carcinogenesis of endometrium. Cancer Lett 2005; 219:33-40; PMID: 15694662; DOI: 10.1016/j.canlet.2004.06.044.
18. Ghabreau L, Roux JP, Niveleau A, Fontanière B, Mahe C, Mokni M, et al. Correlation between the DNA global methylation status and progesterone receptor expression in normal endometrium, endometrioid adenocarcinoma and precursors. Virchows Arch 2004; 445:129-34; PMID: 15221375; DOI: 10.1007/ s00428-004-1059-4.
19. Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998; 17:2413-7; PMID: 9811473; DOI: 10.1038/sj.onc.1202178.
20. Simpkins SB, Bocker T, Swisher EM, Mutch DG, Gersell DJ, Kovatich AJ, et al. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet 1999; 8:661-6; PMID: 10072435; DOI: 10.1093/hmg/8.4.661.
21. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993; 53:5100-3; PMID: 8221644 .
22. Levine RL, Cargile CB, Blazes MS, van Rees B, Kurman RJ, Ellenson LH. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 1998; 58:3254-8; PMID: 9699651.
23. Velasco-Miguel S, Buckbinder L, Jean P, Gelbert L, Talbott R, Laidlaw J, et al. PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes. Oncogene 1999; 18:127-37; PMID: 9926927; DOI: 10.1038/sj.onc.1202274 .
24. Enomoto T, Inoue M, Perantoni AO, Buzard GS, Miki H, Tanizawa O, et al. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res 1991; 51:5308-14; PMID: 1913654.
25. Ikeda T, Yoshinaga K, Semba S, Kondo E, Ohmori H, Horii A. Mutational analysis of the CTNNB1 (betacatenin) gene in human endometrial cancer: frequent mutations at codon 34 that cause nuclear accumulation. Oncol Rep 2000; 7:323-6; PMID: 10671680.
26. Risinger JI, Maxwell GL, Chandramouli GV, Jazaeri A, Aprelikova O, Patterson T, et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 2003; 63:6-11; PMID: 12517768.
27. Guida M, Sanguedolce F, Bufo P, Di Spiezio Sardo A, Bifulco G, Nappi C, et al. Aberrant DNA hypermethylation of hMLH-1 and CDKN2A/p16 genes in benign, premalignant and malignant endometrial lesion. Eur J Gynaecol Oncol 2009; 30:267-70; PMID: 19697618.
28. Feinstein AR, Horwitz RI. Oestrogen treatment and endometrial carcinoma. BMJ 1977; 2:766-7; PMID: 562213; DOI: 10.1136/bmj.2.6089.766-b.
29. Utian WH. Oestrogen therapy and endometrial cancer. BMJ 1977; 2:577-8; PMID: 890429; DOI: 10.1136/ bmj.2.6086.577-c.
30. Issa JP. CpGisland methylator phenotype in cancer. Nat Rev Cancer 2004; 4:988-93; PMID: 15573120; DOI: 10.1038/nrc1507.
31. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity and mortality from cancer in a prospectively studied cohort of USadults. N Engl J Med 2003; 348:1625-38; PMID: 12711737; DOI: 10.1056/NEJMoa021423.
32. Garcia SB, Park HS, Novelli M, Wright NA. Field cancerization, clonality and epithelial stem cells: the spread of mutated clones in epithelial sheets. J Pathol 1999; 187:61-81; PMID: 10341707; DOI: 10.1002/(SICI)1096-9896(199901)187: 1〈61::AIDPATH247〈 3.0.CO;2-I.
33. Chiang S, Oliva E. Cytogenetic and molecular aberrations in endometrial stromal tumors. Hum Pathol 2011; 42:609-17; PMID: 21420714; DOI: 10.1016/j. humpath.2010.12.005.
34. Costello JF, Plass C. Methylation matters. J Med Genet 2001; 38:285-303; PMID: 11333864; DOI: 10.1136/ jmg.38.5.285.
35. Furlan D, Carnevali I, Marcomini B. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clin Cancer Res 2006; 12:3329-36; PMID: 16740754; DOI: 10.1158/1078-0432.CCR-05- 2679.
36. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042-54; PMID: 14627790; DOI: 10.1056/NEJMra023075.
37. Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, Kantarjian HM, et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 2002; 8:2217-24; PMID: 12114423.
38. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000; 60:1835-9; PMID: 10766168.
39. Shen L, Ahuja N, Shen Y, Habib NA, Toyota M, Rashid A, et al. DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst 2002; 94:755-61; PMID: 12011226.
40. Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005; 129:837-45; PMID: 16143123; DOI: 10.1053/j.gastro.2005.06.020.
41. Kusano M, Toyota M, Suzuki H, Akino K, Aoki F, Fujita M, et al. Genetic, epigenetic and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 2006; 106:1467-79; PMID: 16518809; DOI: 10.1002/cncr.21789.
42. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 2005; 65:8961-7; PMID: 16204069; DOI: 10.1158/0008-5472.CAN-05-1187.
43. Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y, et al. CpGisland methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 2005; 65:828-34; PMID: 15705880.
44. Clark SJ, Melki J. DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene 2002; 21:5380-7; PMID: 12154400; DOI: 10.1038/ sj.onc.1205598.
45. Whitcomb BP, Mutch DG, Herzog TJ, Rader JS, Gibb RK, Goodfellow PJ. Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin Cancer Res 2003; 9:2277-87; PMID: 12796396.
46. Mhawech P, Benz A, Cerato C, Greloz V, Assaly M, Desmond JC, et al. Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. Mod Pathol 2005; 18:340-8; PMID: 15257317; DOI: 10.1038/modpathol. 3800240.
47. Yeh KT, Yang MY, Liu TC, Chen JC, Chan WL, Lin SF, et al. Abnormal expression of period 1 (PER1) in endometrial carcinoma. J Pathol 2005; 206:111-20; PMID: 15809976; DOI: 10.1002/path.1756.
48. Yoshida H, Broaddus R, Cheng W, Xie S, Naora H. Deregulation of the HOXA10 homeobox gene in endometrial carcinoma: role in epithelial-mesenchymal transition. Cancer Res 2006; 66:889-97; PMID: 16424022; DOI: 10.1158/0008-5472.CAN-05-2828.
49. Herman JG. Hypermethylation of tumor suppressor genes in cancer. Semin Cancer Biol 1999; 9:359-67; PMID: 10547344; DOI: 10.1006/scbi.1999.0138.
50. An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 2005; 11:656-63; PMID: 15701853.
51. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260:816-9; PMID: 8484122; DOI: 10.1126/ science.8484122.
52. Caduff RF, Johnston CM, Svoboda-Newman SM, Poy EL, Merajver SD, Frank TS. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 1996; 148:1671- 8; PMID: 8623934.
53. Goodfellow PJ, Buttin BM, Herzog TJ, Rader JS, Gibb RK, Swisher E, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci USA 2003; 100:5908-13; PMID: 12732731; DOI: 10.1073/pnas.1030231100.
54. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004; 444:213-23; PMID: 14747944; DOI: 10.1007/ s00428-003-0947-3.
55. Kanaya T, Kyo S, Maida Y, Yatabe N, Tanaka M, Nakamura M, et al. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene 2003; 22:2352- 60; PMID: 12700670; DOI: 10.1038/sj.onc.1206365.
56. Castoria G, Migliaccio A, Green S, Di Domenico M, Chambon P, Auricchio F. Properties of a purified estradiol-dependent calf uterus tyrosine kinase. Biochemistry 1993; 32:1740-50; PMID: 7679922; DOI: 10.1021/bi00058a007.
57. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, et al. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 1998; 17:2008-18; PMID: 9524123; DOI: 10.1093/ emboj/17.7.2008.
58. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, et al. Sex steroid hormones act as growth factors. J Steroid Biochem Mol Biol 2002; 83:31-5; PMID: 12650699; DOI: 10.1016/S0960- 0760(02)00264-9.
59. Vicent GP, Ballaré C, Nacht AS, Clausell J, Subtil- Rodríguez A, Quiles I, et al. Convergence on chromatin of non-genomic and genomic pathways of hormone signaling. J Steroid Biochem Mol Biol 2008; 109:344-9; PMID: 18417338; DOI: 10.1016/j. jsbmb.2008.03.015.
60. Beato M. Transcriptional control by nuclear receptors. FASEB J 1991; 5:2044-51; PMID: 2010057.
61. Beato M, Chávez S, Truss M. Transcriptional regulation by steroid hormones. Steroids 1996; 61:240-51; PMID: 8733009; DOI: 10.1016/0039-128X(96) 00030-X.
62. Ballaré C, Uhrig M, Bechtold T, Sancho E, Di Domenico M, Migliaccio A, et al. Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol 2003; 23:1994-2008; PMID: 12612073; DOI: 10.1128/MCB.23.6.1994-2008.2003.
63. Migliaccio A, Castoria G, Di Domenico M, Ballaré C, Beato M, Auricchio F. The progesterone receptor/estradiol receptor association and the progestin-triggered S-phase entry. Ernst Schering Res Found Workshop 2005; 52:39-54; PMID: 15704467; DOI: 10.1007/3- 540-27147-3-3.
64. Vang R, Tavassoli FA. Proliferative mucinous lesions of the endometrium: analysis of existing criteria for diagnosing carcinoma in biopsies and curettings. Int J Surg Pathol 2003; 11:261-70; PMID: 14615821; DOI: 10.1177/106689690301100403.
65. Marsit CJ, Okpukpara C, Danaee H, Kelsey KT. Epigenetic silencing of the PRSS3 putative tumor suppressor gene in non-small cell lung cancer. Mol Carcinog 2005; 44:146-50; PMID: 16013053; DOI: 10.1002/mc.20125.
66. Chan AO, Broaddus RR, Houlihan PS, Issa JP, Hamilton SR, Rashid A. CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol 2002; 160:1823-30; PMID: 12000733; DOI: 10.1016/S0002-9440(10)61128-5.
67. Yamashita K, Yamaguchi Y, Miyazaki M, Nakamura H, Shimizu H, Maeda H. Sequence-selective DNA detection using multiple laminar streams: a novel microfluidic analysis method. Lab Chip 2004; 4:1-3; PMID: 15007428; DOI: 10.1039/b311571b.
68. Pannone G, Bufo P, Santoro A, Franco R, Aquino G, Longo F, et al. WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors. Oncol Rep 2010; 24:1035-41; PMID: 20811686.